Table 4.
Follow-up outcomes of patients in different age groups.
| Variables | Patients aged ≤45 years | Patients aged >45 years | P-value |
|---|---|---|---|
| (n = 2,001) | (n = 20,527) | ||
| Adverse events at 2-year follow-up | |||
| All-cause death | 29 (1.5) | 1,583 (7.9) | <0.0001 |
| Recurrent myocardial infarction | 35 (1.8) | 406 (2.2) | 0.3635 |
| Stroke | 11 (0.6) | 229 (1.2) | 0.0127 |
| MACCE | 73 (3.8) | 2,112 (10.6) | <0.0001 |
| All-cause readmission | 407 (21.3) | 6,027 (31.7) | <0.0001 |
| Rehospitalization for heart failure | 58 (3.0) | 1,536 (8.1) | <0.0001 |
| Medications at 30-day follow-up | |||
| Antiplatelet therapy | <0.0001 | ||
| Dual antiplatelet therapy | 1,508 (91.8) | 14,196 (86.9) | |
| Single antiplatelet therapy | 114 (6.9) | 1,731 (10.6) | |
| None | 20 (1.2) | 413 (2.5) | |
| ACEI/ARB | 992 (61.4) | 9,471 (59.0) | 0.0665 |
| β blockers | 1,285 (79.1) | 11,602 (71.5) | <0.0001 |
| Statins | 1,565 (95.4) | 15,500 (94.9) | 0.3163 |
| Medications at 6-month follow-up | |||
| Antiplatelet therapy | <0.0001 | ||
| Dual antiplatelet therapy | 1,297 (86.4) | 11,877 (80.3) | |
| Single antiplatelet therapy | 165 (11.0) | 2,365 (16.0) | |
| None | 40 (2.7) | 554 (3.7) | |
| ACEI/ARB | 860 (58.0) | 8,056 (55.4) | 0.0584 |
| β blockers | 1,111 (74.7) | 10,139 (69.1) | <0.0001 |
| Statins | 1,399 (93.5) | 13,713 (92.7) | 0.2803 |
| Medications at 12-month follow-up | |||
| Antiplatelet therapy | <0.0001 | ||
| Dual antiplatelet therapy | 943 (72.5) | 8,332 (65.9) | |
| Single antiplatelet therapy | 312 (24.0) | 3,700 (29.3) | |
| None | 45 (3.5) | 611 (4.8) | |
| ACEI/ARB | 708 (55.5) | 6,576 (52.9) | 0.0743 |
| β blockers | 941 (72.9) | 8,545 (68.1) | 0.0003 |
| Statins | 1,164 (89.9) | 11,453 (90.7) | 0.3196 |
MACCE, major adverse cardiac and cerebrovascular events; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker. Data are reported as n (%).